Recombinant SARS-CoV-2 Spike S1-Fc-Avi Protein

Recombinant SARS-CoV-2 Spike S1-Fc-Avi Protein

Biotinylated Recombinant SARS Spike RBD

Biotinylated Recombinant SARS Spike RBD

Recombinant SARS-CoV-2 Spike S Protein

His-tagged and Fc-fused recombinant SARS-CoV-2 spike protein S1 subunits and RBD, and the biotinylated S1 subunit and RBD versions are available. Biological activity of the SARS-CoV-2 spike protein are tested.

$350.00
In stock
CatalogBP003057

BP003057: Recombinant SARS-CoV-2 Spike S-Fc-Avi Protein

Source: recombinant SARS-CoV-2 Spike S Protein (Gln14-Trp1212) was expressed in mammalian cells with a Fc tag and Avi at the C-terminus.
Accession: QHD43416.1
Predicted molecular mass: 160.7 kDa.
Endotoxin: Less than 1 EU per ug by the LAL method.
Formulation: The recombinant SARS-CoV-2 Spike S protein was lyophilized from 0.22 um filtered solution in 20 mM PB (pH 7.4). Normally 5% trehalose is added as protectant before lyophilization.
Purity: > 95% by PAGE under reduced condition, and SEC-HPLC.

Shipping: The product is shipped with ice packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution.

Background

The SARS-CoV-2 spike (S) glycoprotein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of virus entry inhibitors, neutralizing antibodies, and vaccines. The virus causing Coronavirus Disease 2019 (COVID-19) was named 2019 novel coronavirus (2019-nCoV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are four major structural proteins in SARS-CoV-2, spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins.

There are two subunits, S1 and S2, in the SARS-CoV-2 spike (S) glycoprotein. The furin cleavage site at the boundary between the S1/S2 subunits is processed during biogenesis and sets this virus apart from SARS-CoV and SARS-related CoVs. The S1 subunit, the N-terminal 14-685 amino acids of S protein, contains N-terminal domain (NTD), receptor binding domain (RBD), and receptor binding motif (RBM). The C-terminal S2 subunit contains fusion peptide (FP), heptad repeat 1 (HR1), heptad repeat 2 (HR2), transmembrane domain (TM), and cytoplasmic domain (CP). The SARS-CoV and SARS-CoV-2 S proteins mediate viral entry into host cells by binding to a host receptor, angiotensin-converting enzyme 2 (ACE2), through the receptor-binding domain (RBD) in the S1 subunit, and then fusing the viral and host membranes through the S2 subunit. The binding of the S1 subunit to the extracellular peptidase domain of ACE2 on the surface of cells results in endocytosis and translocation of both the virus and the enzyme into endosomes located within cells. This entry process also requires priming of the S protein by the host serine protease TMPRSS2, which is a potential drug for inhibition.

Two trimeric SARS-CoV-2 spike proteins bind to an ACE2 dimer with the collectrin-like domain of ACE2 mediating homodimerization. The ACE2-binding affinity of the Spike RBD of SARS-CoV-2 is 10- to 20-fold higher than that of SARS-CoV. It was also reported that the affinity is similar. The difference in the affinity measurement may result from a variety of factors, such as S and rhACE2 protein fragments used, and measurement methods.

Please ask for a quote if you need Spike protein mutants or a S protein with different modification or components.

To check more Syd Labs SARS-CoV-2 (2019-nCoV) Antigen and Antibody Reagents and Discovery Services

Write Your Own Review
Only registered users can write reviews. Please Sign in or create an account